Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison

Expert Review of Hematology
Sam KeepingArun Balakumaran

Abstract

There is significant unmet need among patients with relapsed and refractory classical Hodgkin's lymphoma (RRcHL) who have failed multiple lines of therapy, including brentuximab vedotin (BV). Pembrolizumab, an immune checkpoint inhibitor, is one possible treatment solution for this population. The objective of this study was to compare progression-free survival (PFS) with standard of care (SOC) versus pembrolizumab in previously BV treated RRcHL patients. A systematic literature review identified one observational study of SOC that was suitable for comparison with KEYNOTE-087, the principal trial of pembrolizumab in this population. Both naïve and population-adjusted (using outcomes regression) pairwise indirect comparisons were conducted. The primary analysis included all patients who had failed BV, with a secondary analysis conducted including only those known to have failed BV that was part of definitive treatment. In the primary analysis, SOC was inferior to pembrolizumab in both the unadjusted comparison (HR 5.00 [95% confidence interval (CI) 3.56-7.01]) and the adjusted comparison (HR 6.35 [95% CI 4.04-9.98]). These HRs increased to 5.16 (95% CI 3.61-7.38) and 6.56 (95% CI 4.01-10.72), respectively, in the secondary analy...Continue Reading

References

Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David B DugganBruce A Peterson
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter W M JohnsonUNKNOWN United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)
May 21, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jeroen P JansenWiro Stam
Jan 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo FedericoUNKNOWN HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
Sep 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter J HoskinPeter W M Johnson
Jan 26, 2011·Blood·John KuruvillaMichael Crump
Jul 22, 2011·The New England Journal of Medicine·Simonetta VivianiUNKNOWN Intergruppo Italiano Linfomi
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
Jul 28, 2012·Lancet·William Townsend, David Linch
Aug 8, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alden A MocciaLaurie H Sehn
Mar 20, 2013·Seminars in Hematology·Theodoros P Vassilakopoulos, Maria K Angelopoulou
Nov 22, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Matthew MeiRobert Chen
Mar 20, 2014·Journal of Hematology & Oncology·Nancy L BartlettAndres Forero-Torres
Sep 4, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D A EichenauerUNKNOWN ESMO Guidelines Working Group
Apr 20, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Y CheahM A Fanale
Sep 13, 2016·CA: a Cancer Journal for Clinicians·Lauren R TerasChristopher R Flowers
Apr 26, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert ChenUNKNOWN KEYNOTE-087
Aug 22, 2017·Medical Decision Making : an International Journal of the Society for Medical Decision Making·David M PhillippoNicky J Welton

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Bacterial Vaginosis

Bacterial vaginosis can increase the risk of sexually transmitted infections and in rare cases lead to pelvic inflammatory diseases. Discover the latest research on Bacterial Vaginosis here.